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OBJECTIVES The purpose of the study was to examine the association between white blood cell (WBC)
count on admission and 30-day mortality in patients with acute myocardial infarction (AMI).
BACKGROUND Elevations in WBC count have been associated with the development of AMI and with
long-term mortality in patients with coronary artery disease. However, the relationship
between WBC count and prognosis following AMI is less clear.
METHODS Using the Cooperative Cardiovascular Project database, we evaluated 153,213 patients 65
years of age admitted with AMI.
RESULTS An increasing WBC count is associated with a significantly higher risk of in-hospital events,
in-hospital mortality and 30-day mortality. Relative to those patients in the lowest quintile,
patients in the highest quintile were three times more likely to die at 30 days (10.3% vs.
32.3%; p  0.001). After adjustment for confounding factors, WBC count was found to be
a strong independent predictor of 30-day mortality (odds ratio  2.37; 95% confidence
interval 2.25 to 2.49, p  0.0001 for the highest quintile of WBC count).
CONCLUSIONS White blood cell count within 24 h of admission for an AMI is a strong and independent
predictor of in-hospital and 30-day mortality as well as in-hospital clinical events. Although
the mechanism of the association remains speculative, the results of this study have important
clinical implications for risk-stratifying patients with AMI. (J Am Coll Cardiol 2001;38:
1654–61) © 2001 by the American College of Cardiology
Inflammation is thought to play a key role in the develop-
ment of coronary artery disease as well as in the pathogen-
esis of coronary thrombosis (1). Elevations in white blood
cell (WBC) count have been associated with development of
coronary heart disease (2–9) as well as with long-term
mortality in patients with known coronary artery disease
(10–12). Krumholz et al. recently demonstrated (13) that
WBC count was a strong independent predictor of mortal-
ity in acute myocardial infarction (AMI) as well. They
analyzed data on 82,359 patients 65 years of age admitted
with AMI to 2,401 hospitals and developed a model that
predicted 30-day mortality (13). Of the 73 variables of
candidate predictors examined, the seven most important
variables were age, cardiac arrest, anterior or lateral location
of myocardial infarction, systolic blood pressure, serum
creatinine, congestive heart failure and WBC count. The
purpose of the present analysis is to better characterize the
relationship between the WBC count and 30-day mortality
and specifically examine this association in many different
subgroups. A greater understanding of this relationship
could be helpful in risk stratifying patients with AMI, as
WBC count is inexpensive and routinely measured on
admission. Furthermore, such an association, if present,
could lend epidemiologic support to the hypothesis that
leukocytes are involved in myocardial damage following
reperfusion therapy (6,14), as well as support the findings
from an angiographic study in which an increased WBC
count was associated with a hypercoagulable state (15).
Thus, the purpose of the present study was to explore the
association between WBC count and 30-day mortality
following AMI in a very large, geographically diverse co-
hort of patients 65 years of age. In addition, we sought
to compare the impact of WBC count on 30-day mortality
by age, gender, smoking status and use of reperfusion
therapy.
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METHODS
Data sources. THE COOPERATIVE CARDIOVASCULAR
PROJECT (CCP) DATABASE. The CCP database has been
described previously (16). In brief, it includes more than
200,000 patients hospitalized across the country with a
principal discharge diagnosis of AMI (International Classi-
fication of Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] 410) in 1994 and 1995. Trained technicians
abstracted predefined demographic, clinical and treatment
variables from copies of the hospital records and entered
them directly into a computer database using interactive
software. For all CCP samples, 3,000 records were reab-
stracted, with overall variable agreement of 95%.
MEDICARE ENROLLMENT DATABASE. The Medicare En-
rollment Database contains accurate records of the vital
status of Medicare beneficiaries, but entries from the social
security records include unverified dates of death that were
recorded as the last day of the month when the exact date
from a death certificate was unavailable. We eliminated
cases with unverified dates of death from the mortality
analysis if mortality could not be classified with certainty at
the time of evaluation, as described in an earlier report (17).
We found unverified dates of death for 325 patients in our
sample (0.1% of such patients or 0.8% of deaths).
Study sample. The overall study sample was restricted to
patients 65 years of age who had confirmed AMI, as
previously reported (16), and who were not received in
transfer from another institution (Table 1). To avoid count-
ing patients more than once, we included only a patient’s
first confirmed AMI hospitalization in the CCP database.
We also excluded patients with WBC count 500 mm3 or
50,000 mm3, patients whose WBC value was missing and
patients with a terminal illness or metastatic cancer.
Study variables. The main outcome variable of the study
was mortality within 30 days from admission. This infor-
mation was ascertained from the Medicare Enrollment
Database, which was derived from the Master Beneficiary
Record from Social Security Administration data, a valid
source of vital status (18). Other outcomes were in-hospital
mortality and in-hospital events.
In our analysis, the cohort of patients was divided into
five groups based on the quintiles of their admission WBC
count. White blood cell count was defined as the first value
documented in the medical record within 24 h of admission.
If no WBC count was recorded, the closest value within
24 h before admission was used.
Missing observations exceeded 5% for the following
candidate predictor variables: angina, time since chest pain
started, evidence of heart failure or pulmonary edema on
chest x-ray, location of AMI, ventricular tachycardia,
height, weight, albumin, atrial fibrillation/flutter, heart
block on electrocardiogram, left or right bundle branch
block and paced rhythm. Values for continuous variables
outside the following ranges were considered implausible
and set to missing: respiratory rate 80 breaths/min,
systolic blood pressure 300 mm Hg, diastolic blood
pressure 150 mm Hg, serum urea nitrogen 200 mg/dl,
creatinine 25 mg/dl, and albumin 20 mg/dl. Observa-
tions with missing values for myocardial infarction location
and radiographic evidence of heart failure were set to null.
Alternative methods for controlling missing values, such as
including dummy variables indicating missing observations
or restricting the analysis to observations without any
missing values, did not substantially affect model estimates,
calibration or our conclusions.
Statistical analysis. First, we sought to examine bivariate
associations of patient clinical and demographic character-
istics with WBC count quintiles, and then we described the
impact of WBC count quintiles on outcomes. Continuous
variables were dichotomized or categorized based on clinical
significance as shown in the tables. Missing values were
coded as characteristics not present. Statistical significance
of associations was tested using the chi-square statistic.
The associations between WBC count quintiles and
30-day mortality from admission was evaluated using logis-
tic regression models. Clinical characteristics previously
reported to be associated with AMI mortality were included
in the models. These characteristics included gender, age,
race, medical history (hypertension, diabetes, smoking, de-
mentia, AMI, heart failure, coronary bypass grafting, per-
cutaneous transluminal coronary angioplasty, stroke,
chronic obstructive pulmonary disease, peripheral vascular
disease/claudication, angina/chest pain), admission charac-
teristics (cardiac arrest, shock, hemorrhage, cardiomegaly,
atrial fibrillation/flutter, ST elevation, left and right bundle
Abbreviations and Acronyms
AMI  acute myocardial infarction
CCP  Cooperative Cardiovascular Project
CI  confidence interval
CK  creatine phosphokinase
ICD-9-CM  International Classification of Diseases,
9th Revision, Clinical Modification
OR  odds ratio
TIMI  Thrombolysis In Myocardial Infarction
WBC  white blood cell
Table 1. Study Logic (Inclusions and Exclusions)
Total sample 234,769
Exclusions*
Age  65 yrs 17,593 (7.5%)
AMI not confirmed 31,186 (13.3%)
Transfer in 34,409 (14.7%)
Repeat hospitalizations† 23,773 (10.6%)
WBC count unknown or out of range‡ 12,893 (5.5%)
Terminal illness or metastatic cancer 4,617 (2.0%)
Unverified death 325 (0.1%)
Discharge date beyond study period 77 (0.0%)
Study sample 153,213
*Not mutually exclusive; †repeat hospitalizations occurred in 22,187 patients; ‡Range
is (0.5 to 50) in thousands.
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branch block, old AMI, heart block, systolic and diastolic
blood pressure, heart rate, respiratory rate, creatinine, blood
urea nitrogen, sodium, glucose, albumin), treatments ad-
ministered (aspirin, angiotensin-converting enzyme inhibi-
tor, beta-blocker, primary percutaneous transluminal coro-
nary angioplasty, and thrombolytic therapy), and peak
creatinine phosphokinase (CK) values. Factors other than
WBC count that were independently associated with 30-
day mortality were identified using a logistic regression model
and stepwise selection method (entry significance level 
0.0005 and exit significance level  0.0001). Subgroup anal-
yses were also performed in men and women and in various age
groups (65 to 74 years, 75 to 84 years and 85 years).
Odds ratios (OR) and 95% confidence intervals (CI) were
calculated using logistic regression models with and without
adjusting for confounding effects. All these analyses were
done by using PC-SAS 6.12 software 1989 to 1996 (SAS
Institute Inc., Cary, North Carolina).
Table 2. Baseline Characteristics Among WBC Count Quintile (%)*
Characteristic
(WBC count range) Total
Quintile 1
(<7.5)
Quintile 2
(7.5–9.1)
Quintile 3
(9.1–10.9)
Quintile 4
(11.0–13.6)
Quintile 5
(>13.6)
Demographics
Age 75 yrs 56% 56% 54% 54% 55% 59%
Gender: Female 49% 45% 47% 49% 50% 55%
Race: White 90% 86% 90% 91% 92% 92%
Medical history
Congestive heart failure 21% 18% 18% 19% 22% 29%
Myocardial infarction 29% 31% 30% 29% 28% 28%
Diabetes mellitus 31% 25% 28% 30% 33% 38%
Hypertension 62% 61% 61% 62% 63% 63%
CVA/stroke 14% 12% 12% 13% 15% 18%
Angina/chest pain 45% 50% 48% 46% 45% 39%
Cigarette smoker 15% 10% 13% 16% 18% 18%
CABG surgery 13% 16% 15% 14% 12% 10%
PTCA 7% 8% 8% 7% 6% 5%
PVD/claudicating 10% 9% 9% 10% 11% 12%
COPD 20% 16% 17% 20% 22% 26%
Dementia/Alzheimer’s disease 6% 5% 5% 5% 6% 9%
Clinical symptoms
Cardiac arrest 4% 2% 2% 3% 4% 7%
Congestive heart failure 60% 52% 55% 58% 64% 74%
Angina 60 min after arrival 37% 39% 40% 40% 38% 27%
Temperature 100.4°F 2% 1% 1% 1% 2% 4%
Heart rate 100 beats/min 26% 16% 18% 22% 28% 43%
Respiratory rate 25 breaths/min 20% 11% 13% 16% 22% 37%
ECG characteristics
ST elevation 29% 24% 28% 30% 32% 33%
LBBB 10% 8% 9% 9% 10% 14%
RBBB 12% 11% 12% 12% 13% 13%
Atrial fibrillation/flutter 21% 18% 19% 20% 23% 27%
Heart block, 2nd or 3rd 4% 3% 4% 4% 5% 6%
Location of MI
Anterior 46% 42% 44% 46% 48% 51%
Lateral 29% 25% 27% 29% 31% 31%
Posterior 10% 9% 10% 10% 10% 9%
Inferior 47% 44% 46% 48% 48% 47%
Other 9% 9% 9% 9% 10% 9%
Laboratory data
Albumin 3 g/dl 68% 68% 69% 68% 68% 65%
Creatinine  2.25 or BUN  40 mg/dl 10% 7% 7% 8% 11% 18%
Sodium  130 mmol 3% 2% 2% 2% 3% 4%
Peak CK  1,260 25% 17% 21% 25% 29% 32%
Treatments
Aspirin 79% 82% 83% 81% 79% 68%
ACE inhibitor 42% 37% 39% 42% 45% 49%
Reperfusion therapy: PTCA 11% 12% 12% 12% 10% 8%
Reperfusion therapy: TTx 22% 21% 23% 25% 24% 17%
Beta-blocker 49% 53% 53% 52% 49% 39%
*p  0.001 for all variables listed.
ACE  angiotensin-converting enzyme; BUN  blood urea nitrogen; CABG  coronary artery bypass graft surgery; CK  creatine phosphokinase; COPD  chronic
obstructive pulmonary disease; CVA  cerebrovascular accident; ECG  electrocardiogram; LBBB  left bundle branch block; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angioplasty; PVD  peripheral vascular disease; RBBB  right bundle branch block; TTx  thrombolytic therapy.
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RESULTS
There were a total of 153,213 patients included in this
analysis. Table 1 reports the development of the study
sample. Table 2 describes the baseline, demographic and
clinical characteristics of the cohort, divided into quintiles,
as a function of their WBC count. Patients in the highest
quintile were older, more likely women and in general had
more cardiac risk factors and more comorbidities than
patients did in the lowest quintile.
The overall in-hospital mortality and 30-day mortality
rates were 14.7% and 18.4% respectively. There was a
significantly higher risk of in-hospital events, in-hospital
mortality and 30-day mortality with increasing WBC count
(Table 3). Relative to patients in the lowest quintile,
patients in the highest quintile were three times more likely
to die at 30 days (10.3% vs. 32.3%; p  0.001). Approxi-
mately one-third of the patients had an elevated WBC
count (defined as 12 mm3) on admission (Table 4). These
patients were more than twice as likely to die as those
patients with a normal WBC count (defined as 6 to 12) and
almost three times as likely as those with a low WBC count
(defined as 6). The increased mortality in patients with
higher WBC counts was seen in all subgroups examined
(Table 5 and Fig. 1).
A multivariate model was developed to identify all the
predictors of 30-day mortality. All variables in Table 2 were
included in the logistic regression analysis and entered in a
stepwise method. After adjustment for these factors, WBC
count was found to be a strong independent predictor of
30-day mortality (Tables 6 and 7). Relative to those patients
in the lowest quintile, there was a 2.4-fold increase in the
odds of death in patients in the highest quintile (OR 
2.37; 95% CI 2.25 to 2.49, p  0.0001). This effect did not
differ in men versus women or in patients aged 75 years
compared with those aged 75 years (Tables 6 and 7).
DISCUSSION
In the present study we observed a strong independent
association between increasing WBC count and 30-day
mortality. This effect was present in both men and women,
was observed in all age groups and was seen in patients who
received reperfusion therapy as well as those who did not.
Patients with a WBC count in the highest quintile had a
30-day mortality rate that was 3 times higher than that of
patients with a WBC count in the lowest quintile.
In 1974, Friedman et al. (2) first described the association
between WBC count and coronary heart disease. These
investigators found that an increased WBC count increased
the risk of developing a first AMI. Numerous other studies
subsequently confirmed this observation (3–9). Schlant et al.
(11) were the first to document an elevation in WBC count
as a predictor of all-cause mortality in patients who survived
an AMI. Others also confirmed these findings (10,12). In
none of the above studies, however, was the short-term
prognostic importance of the WBC count measured during
the acute phase of the AMI assessed.
Furman et al. (19) examined the association between
WBC count and mortality using data from the Worcester
Heart Attack Study. Consistent with the findings from the
present study, these investigators found that WBC count
was significantly associated with in-hospital survival. Rela-
tive to those patients with the lowest WBC count, patients
in the highest quintile of WBC count had 71% greater odds
of dying from their AMI (OR  1.71, 95% CI  1.14 to
2.58). More recently, Barron et al. (15) examined the
association between WBC count and angiographic findings
in the Thrombolysis In Myocardial Infarction (TIMI) 10A
and TIMI 10B data set. They found that patients with a
closed infarct-related artery at 60 and 90 min had a higher
WBC count than patients with an open artery. Further-
more, angiographically apparent thrombus was associated
with a higher WBC count. The present study extends these
observations in a much larger and less selective data set and
clarifies that the response is graded and that there are no
interactions between age and gender.
Table 3. Outcomes in WBC Count Groups
WBC Range Total No.
In-Hospital Event*
No. (%)†
In-Hospital Death
No. (%)†
Death at 30 Days
No. (%)†
Quintile 1 (0.6–7.5) 30,639 19,032 (62.12) 2,346 (7.66) 3,148 (10.27)
Quintile 2 (7.5–9.1) 31,267 19,748 (63.16) 2,981 (9.53) 3,947 (12.62)
Quintile 3 (9.1–10.9) 30,388 19,664 (64.71) 3,796 (12.49) 4,894 (16.11)
Quintile 4 (11.0–13.6) 30,154 20,759 (68.84) 4,944 (16.40) 6,230 (20.66)
Quintile 5 (13.6–49.8) 30,765 23,573 (76.63) 8,436 (27.26) 9,943 (32.32)
Total (0.6–49.8) 15,213 102,777 (67.08) 22,453 (14.65) 28,162 (18.38)
*Events included evidence of bradycardia, shock or heart failure during the index admission; †there were significant differences among quintiles and increasing trend among
quintiles.
WBC  white blood cell.
Table 4. Outcomes in WBC Groups
WBC Total No.
In-Hospital
Death (%)*
Died in 30
Days (%)*
6 10,209 786 (7.70) 1,022 (10.01)
6–12 96,637 10,449 (10.81) 13,656 (14.13)
12 46,367 11,218 (24.19) 13,484 (29.08)
Total 153,213 22,453 (14.65) 28,162 (18.38)
*p  0.001.
WBC  white blood cell.
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The role of neutrophils in animal models of ischemia-
reperfusion. The data from the current study as well as
those from the study by Barron et al. (15) are consistent
with the fact that WBCs may in some way be linked to the
cause of the increased mortality (i.e., WBCs are in the
causal pathway). In animal models of ischemia-reperfusion,
neutrophils appear to lead to infarct expansion (20). In a
canine model of AMI, neutrophil depletion was associated
with a marked reduction in infarct size (21). The mecha-
nism by which neutrophils cause this damage is unclear.
Engler et al. (14) and others have documented that reper-
fusion following prolonged ischemia leads to progressive
leukocyte capillary plugging and the “no reflow” phenome-
non. This plugging likely results in part from neutrophils
binding to the ischemic endothelium via the leukocyte
integrin CD11b/CD18 (Mac-1) receptor (22). Three ani-
mal studies have demonstrated that treatment with an
antibody to the CD18 receptor on neutrophils reduces
infarct size (23–25). Furthermore, a receptor knockout
experiment in rodents also suggested a role for neutrophils
in increasing infarct size (26).
Another mechanism by which WBCs could cause in-
creased mortality is by inducing a hypercoagulable state. We
have recently reported that an increased WBC count was
associated with lower rates of coronary patency and in-
creased thrombus burden in patients with AMI treated with
Figure 1. Thirty-day mortality rate by white blood cell (WBC) count quintiles and genders.
Table 5. Thirty-Day Mortality in Patients With AMI by WBC Count Quintile (%)
Subgroup
Quintile 1
(<7.5)
Quintile 2
(7.5–9.1)
Quintile 3
(9.1–10.9)
Quintile 4
(11.0–13.6)
Quintile 5
(>13.6)
Age  75 yrs 13% 17% 21% 26% 38%
Race: white 10% 12% 16% 21% 33%
Diabetes mellitus 11% 14% 17% 22% 33%
Cigarette smoker 9% 10% 12% 15% 24%
Prior stroke 14% 17% 22% 27% 39%
Angina/chest pain 9% 12% 15% 19% 30%
Prior MI 11% 13% 17% 22% 31%
Congestive heart failure 17% 20% 24% 27% 35%
PVD/claudicating 14% 16% 20% 23% 33%
Hypertension 10% 12% 16% 20% 30%
COPD 12% 14% 16% 20% 30%
CABG surgery 10% 12% 15% 21% 32%
PTCA 7% 9% 11% 13% 24%
Angina  60 min after arrival 9% 12% 14% 19% 28%
Temperature 100.4°F 18% 19% 20% 23% 34%
Albumin  3 g/dl 9% 11% 15% 19% 29%
Creatinine  2.5 mg/dl or BUN  40 mg/dl 28% 29% 35% 38% 49%
ST elevation 13% 14% 18% 22% 35%
LBBB 18% 20% 24% 30% 38%
RBBB 16% 19% 24% 33% 44%
Aspirin 8% 10% 12% 16% 23%
ACE inhibitor 11% 13% 16% 19% 25%
Beta-blocker 7% 9% 12% 15% 23%
p  0.001 for all variables listed.
AMI  acute myocardial infarction; other abbreviations as in Table 2.
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thrombolytics (15). It has been hypothesized that this
hypercoagulable state may be mediated by an increased
expression of tissue factor on leukocytes in the setting of
AMI (27). Finally, it is possible that leukocytes release
proinflammatory cytokines that cause myocyte dysfunction
and necrosis (15).
It is possible that the associations between WBC count
and mortality are simply confounded by some unmeasured
covariate that reflects the severity of the initial insult.
Although we did not directly measure the amount of
myocardium at risk or the final infarct size, we did collect
information as to whether the patient developed ST seg-
ment elevation, the infarct location, the symptom duration,
the use of reperfusion therapy, baseline hemodynamic mea-
sures and whether the patient developed congestive heart
failure. Although there was a weak correlation between
WBC count and peak CK (r  0.12), the association
between WBC count and death was independent of this and
other indirect markers of myocardium at risk and final
infarct size. Thus, even though the association between
WBC count and mortality may be partly explained by the
association with larger infarcts, the present study clearly
demonstrates that the WBC count on admission adds
important additional information to risk-stratify patients
following AMI. One other potential confounding factor is
underlying infection. Several findings from this study sug-
gest that this was not the case. First, 96% of the patients in
the highest quintile of WBC count did not have an elevated
temperature recorded on admission. Furthermore, when we
excluded patients who were thought to have pneumonia on
admission or who developed pneumonia during their hos-
pitalization, our findings remained identical. Also, because
we observed that increasing WBC count was associated
with the development of other adverse events such as
congestive heart failure, we believe that this is an unlikely
explanation for the observed association.
Study limitations. There are several important limitations
to the study. First, it is not possible to determine if the
WBC count is a risk factor for adverse outcomes or a
marker. Second, although we did measure peak CK levels,
we did not directly measure several other potentially impor-
tant indicators of the severity of the AMI, such as infarct
size, the degree of ST segment elevation resolution or
coronary artery patency. Lastly, our database did not contain
information regarding the WBC count differential, which
may have contributed important additional information.
Table 6. Association Between WBC Count Quintile and 30-Day Mortality by Age and Gender
Death Unadjusted Adjusted*
n % OR 95% CI p Value OR 95% CI p Value
Overall
Quintile 1 3,148 10.27 1.000 1.000
Quintile 2 3,947 12.62 1.262 (1.200–1.326) 0.0001 1.217 (1.154–1.284) 0.0001
Quintile 3 4,894 16.11 1.676 (1.598–1.759) 0.0001 1.477 (1.402–1.556) 0.0001
Quintile 4 6,230 20.66 2.274 (2.171–2.382) 0.0001 1.751 (1.664–1.842) 0.0001
Quintile 5 9,943 32.32 4.170 (3.991–4.357) 0.0001 2.369 (2.253–2.490) 0.0001
Men
Quintile 1 1,554 9.25 1.000 1.000
Quintile 2 1,878 11.29 1.249 (1.163–1.341) 0.0001 1.192 (1.104–1.286) 0.0001
Quintile 3 2,259 14.44 1.657 (1.547–1.775) 0.0001 1.413 (1.312–1.522) 0.0001
Quintile 4 2,889 19.30 2.347 (2.197–2.507) 0.0001 1.732 (1.610–1.863) 0.0001
Quintile 5 4,305 30.89 4.388 (4.118–4.675) 0.0001 2.358 (2.193–2.535) 0.0001
Women
Quintile 1 1,594 11.52 1.000 1.000
Quintile 2 2,069 14.14 1.265 (1.179–1.356) 0.0001 1.244 (1.154–1.341) 0.0001
Quintile 3 2,635 17.87 1.670 (1.562–1.786) 0.0001 1.534 (1.427–1.650) 0.0001
Quintile 4 3,341 22.01 2.166 (2.031–2.311) 0.0001 1.766 (1.645–1.897) 0.0001
Quintile 5 5,638 33.50 3.868 (3.638–4.112) 0.0001 2.386 (2.226–2.558) 0.0001
Age 75 yrs
Quintile 1 855 6.29 1.000 1.000
Quintile 2 1,100 7.71 1.245 (1.135–1.366) 0.0001 1.183 (1.072–1.306) 0.0008
Quintile 3 1,406 10.04 1.664 (1.523–1.818) 0.0001 1.403 (1.275–1.543) 0.0001
Quintile 4 1,881 13.71 2.369 (2.177–2.578) 0.0001 1.724 (1.572–1.891) 0.0001
Quintile 5 3,061 24.44 4.821 (4.449–5.225) 0.0001 2.394 (2.186–2.622) 0.0001
Age 75 yrs
Quintile 1 2,293 13.46 1.000 1.000
Quintile 2 2,847 16.75 1.294 (1.219–1.373) 0.0001 1.236 (1.160–1.317) 0.0001
Quintile 3 3,488 21.28 1.739 (1.641–1.842) 0.0001 1.522 (1.430–1.619) 0.0001
Quintile 4 4,349 26.46 2.314 (2.188–2.447) 0.0001 1.781 (1.675–1.893) 0.0001
Quintile 5 6,882 68.82 3.896 (3.695–4.109) 0.0001 2.369 (2.231–2.516) 0.0001
*Adjusted by the confounding risk factors.
CI  confidence interval; OR  odds ratio; WBC  white blood cell.
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CONCLUSIONS
In patients with AMI, the WBC count measured within
24 h of admission is a strong and independent predictor of
in-hospital and 30-day mortality as well as in-hospital
clinical events. Although the association is robust, the
mechanism responsible for the association remains specula-
tive. However, regardless of whether the association be-
tween WBC counts and mortality is confounded by an
unmeasured covariate or whether it reflects some funda-
mental pathophysiologic process, the results of this study
have important clinical implications for risk stratifying
patients with AMI.
Reprint requests and correspondence: Dr. Harlan M. Krum-
holz, 333 Cedar Street, P.O. Box 208025, New Haven, Connect-
icut 06520-8025.
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